Fig. 3.

Molecular response. A JAK2 V617F allele burden. B Proportion of patients with ≥ 50% JAK2 V617F allele burden. C Change in JAK2 V617F allele burden over time for patients with < 50% allele burden at week 52. One patient (003–003) discontinued, whose data at week 24 reflect the end of treatment. D Change in JAK2 V617F allele burden over time for patients with ≥ 50% allele burden at week 52. N = 19; data are mean (standard deviation) or percentage. One patient who was negative for JAK2 V617F at baseline was excluded